Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Migraine is a common neurological disorder that can severely affect daily life. Atogepant is a new oral medication designed to prevent migraines. This study reviewed six high-quality trials involving 3,453 patients. Researchers wanted to assess how effective and safe atogepant is for migraine prevention. They looked at several outcomes, including monthly migraine days and headache days. The results showed that atogepant significantly reduced the number of monthly migraine days by about 1.47 days. It also decreased the use of acute migraine medications. Adverse events were monitored, but overall, atogepant was well-tolerated. This research suggests that atogepant could be a valuable option for those suffering from migraines. It offers hope for better management of this debilitating condition. With further studies, it may lead to improved quality of life for many migraine sufferers. Clinical relevance: This research indicates that atogepant is an effective and safe option for migraine prevention, potentially improving treatment outcomes for patients suffering from this debilitating condition.